Showing results (451-460 of 566) with videos related to

Sort By:
Pageof 57
The Journal of Rheumatology|July 5, 2011
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?Lisa K Stamp, Puja P Khanna, Nicola Dalbeth, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2017
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, et al.
The Journal of Rheumatology|February 17, 2019
OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention StudiesMaarten Boers, Dorcas E Beaton, Beverley J Shea, et al.
The Journal of Rheumatology|February 3, 2019
Instrument Selection Using the OMERACT Filter 2.1: The OMERACT MethodologyDorcas E Beaton, Lara J Maxwell, Beverley J Shea, et al.
Annals of the Rheumatic Diseases|June 5, 2026
Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysisTommy K Annfeldt, Mina N Händel, Tobias Haugegaard, et al.
Zeitschrift Fur Rheumatologie|May 5, 2025
[Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany]Katinka Albrecht, Katja Thiele, Tobias Alexander, et al.
Arthritis Care & Research|July 11, 2017
Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International CollaborationSara K Tedeschi, Sindhu R Johnson, Dimitrios Boumpas, et al.
Rheumatology (Oxford, England)|March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2024
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled TrialJoan T Merrill, Yoshiya Tanaka, David D'Cruz, et al.
Pageof 57